Efficacy of benralizumab in severe eosinophilic asthma: an interim analysis of a real clinical practice prospective study BEST in Russia-Reference-Cited by-同舟云学术

Efficacy of benralizumab in severe eosinophilic asthma: an interim analysis of a real clinical practice prospective study BEST in Russia

Published:2023-06-08 Issue:3 Volume:33 Page:374-385
ISSN:2541-9617
Container-title:PULMONOLOGIYA
language:
Short-container-title:Pulʹmonologiâ (Mosk.)

Author:

Fomina D. S.¹^ORCID,Ignatova G. L.²^ORCID,Kabanova T. G.³^ORCID,Kameleva A. A.⁴^ORCID,Kozyreva L. S.⁵^ORCID,Kosyakova N. I.⁶^ORCID,Kudelya L. M.⁷^ORCID,Kuzubova N. A.⁸^ORCID,Leshсhenko I. V.⁹^ORCID,Mukhina O. A.¹⁰^ORCID,Shulzhenko L. V.¹¹^ORCID

Affiliation:

1. Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); State Budgetary Healthcare Institution of Moscow City “Moscow City Clinical Hospital 52”, Moscow Department of Health; Non-profit Joint Stock Company “Astana Medical University”, Ministry of Health of the Republic of Kazakhstan

2. Federal State Budgetary Educational Institution of Higher Education “South Ural State Medical University”, Ministry of Healthcare of Russian Federation

3. State Budgetary Health Institution of the Moscow Region “Moscow Regional Research Clinical Institute named after M.F. Vladimirsky”

4. State Budgetary Healthcare Institution of the City of Moscow “City Clinical Hospital named after D.D. Pletnev of Moscow Department of Health”

5. Federal State Budgetary Educational Institution of Higher Education “Bashkir State Medical University”, Ministry of Healthcare of Russian Federation

6. Federal State Budgetary Institution of Science, Federal Research Center “Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences”, Ministry of Science and Higher Education of the Russian Federation

7. Federal State Budgetary Educational Institution of Higher Education “Novosibirsk State Medical University”, Ministry of Healthcare of Russian Federation; State Budgetary Healthcare Institution of the Novosibirsk region “State Novosibirsk Regional Clinical Hospital”

8. Federal State Budgetary Educational Institution of Higher Education “Academician I.P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian Federation

9. Federal State Budget Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation; Ural Research Institute of Phthisiopulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia; Limited Liability Company “Novaya bol’nitsa” Clinical Association

10. Non-profit Joint Stock Company “Astana Medical University”, Ministry of Health of the Republic of Kazakhstan

11. Federal State Budgetary Educational Institution of Higher Education “Kuban State Medical University” of the Ministry of Health of the Russian Federation; Federal Budgetary Healthcare Institution “Research Institute – Regional Hospital No.1. Named after S.V. Ochapovskiy”

Abstract

Systematizing clinical experience in the use of biological treatments in patients with severe bronchial asthma in real world settings with assessment of clinical outcomes and quality of life level is of great interest and value in practical pulmonology.The aim of the BEST study (Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia) was to evaluate effectiveness of benralizumab by control and quality of life associated with respiratory status in patients with eosinophilic phenotype of severe asthma in real clinical practice in Russia.Results. The results obtained through 16 weeks of benralizumab therapy in patients with severe eosinophilic asthma (SEA) were analyzed. All 59 enrolled patients showed significant improvement in the asthma control questionnaire (ACQ-5) score, the quality of life associated with respiratory status according to the St. George Respiratory Questionnaire (SGRQ), and subjective assessments of the well-being of patients and the disease severity (PGIC and PGIS). Treatment with benralizumab contributed to a reduction in the oral glucocorticosteroids intake throughout the study period.Conclusion. In real clinical practice, treatment with benralizumab results in significant improvement in disease control and the quality of life in patients with severe eosinophilic asthma and is characterized by a favorable safety profile.

Publisher

Scientific and Practical Reviewed Journal Pulmonology

Subject

Pulmonary and Respiratory Medicine

Reference22 articles.

1. Global Initiative for Asthma. 2022 GINA main report. 2022 GINA Report, Global Strategy for Asthma Management and Prevention. Available at: https://ginasthma.org/gina-reports/ [Accessed: April 10, 2023].

2. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 963–974. DOI: 10.2147/COPD.S67283.

3. Price D., Wilson A.M., Chisholm A. et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J. Asthma Allergy. 2016; 9: 1–12. DOI: 10.2147/JAA.S97973.

4. Hillas G., Fouka E., Papaioannou A.I. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev. Respir. Med. 2020; 14 (4): 353–365. DOI: 10.1080/17476348.2020.1718495.

5. Hekking P.P.W., Wener R.R., Amelink M. et al. The prevalence of severe refractory asthma. J. Allergy Clin. Immunol. 2015; 135 (4): 896–902. DOI: 10.1016/j.jaci.2014.08.042.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of benralizumab in severe eosinophilic asthma: results of a real clinical practice prospective study BEST in Russia;PULMONOLOGIYA;2024-05-20